GLPwatch
Bydureon for Alzheimer's disease
exenatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCBydureon (exenatide) is not FDA-approved for Alzheimer's disease, and any use for this condition is off-label or investigational. Research in animal models suggests potential cognitive benefits, but a clinical trial in humans with mild cognitive impairment found no prevention of cognitive decline.
AI summary of the sources below.
| Drug | Bydureon (exenatide) |
|---|---|
| Condition | Alzheimer's disease |
| Approval status | Investigational / off-label |
| Research papers | 16 |
Bydureon is not FDA-approved for alzheimer's disease; the research below reflects investigational or off-label study only.
Research on exenatide for alzheimer's disease (16)
- A Pilot Study of Exenatide Actions in Alzheimer's Disease.
- Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats.
- Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.
- Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer's disease.
- Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice.
- Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.
- Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats.
- Exenatide enhances cognitive performance and upregulates neurotrophic factor gene expression levels in diabetic mice.
- p38<i>β</i> Mitogen-Activated Protein Kinase Signaling Mediates Exenatide-Stimulated Microglial <i>β</i>-Endorphin Expression.
- Peptidic exenatide and herbal catalpol mediate neuroprotection via the hippocampal GLP-1 receptor/β-endorphin pathway.
- Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.
- Exenatide exerts a neuroprotective effect against diabetic cognitive impairment in rats by inhibiting apoptosis: Role of the JNK/c‑JUN signaling pathway.
- The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity.
- Exenatide Is Neuroprotective in a New Rabbit Model of Hypoxia-Ischemia.
- [A case of an elderly diabetic patient with dementia effectively treated with weekly exenatide].
- Liraglutide and Exenatide in Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes.